drugset
drugset / Trial / NCT06170697

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

NCT06170697 ↗

Phase 2 Unknown 46 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

Every year, about 6% of patients with malignant tumors are diagnosed as head and neck cancer. There are about 650000 new cases and 350000 deaths. A considerable number of patients have simple local recurrence in the short term after operation suggesting that the biological behavior of this kind of tumor is relatively more invasive and the overall prognosis is poor. This project intends to study the efficacy and safety of camrelizumab combined with concurrent chemoradiotherapy for short-term postoperative progression of head and neck squamous cell carcinoma.

Timeline

Start
2023-03-01
Primary completion
2024-07
Completion
2025-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Carboplatin Small molecule 2 unknown Intravenous
Subject Cisplatin Other / unclassified 80 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 100 mg/m2 Intravenous
Subject Lobaplatin Small molecule 30 mg/m2 Intravenous
Subject Nedaplatin Small molecule 25 mg/m2 Intravenous
Subject Nedaplatin Small molecule 30 mg/m2 Intravenous

Indications

head and neck squamous cell carcinoma